Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mofesedine mesylate (HEC73518) is an orally bioavailable small molecule capsid assembly modulator (CAM) developed by Dongguan Chang'an Dongyangguang New Drug Research and Development (HEC Pharm) for the treatment of chronic hepatitis B virus (HBV) infection. It functions as a Class II core protein allosteric modulator (CpAM), which misdirects the assembly of the HBV core protein (HBcAg) into empty, non-genomic capsids. This mechanism effectively blocks the encapsidation of pregenomic RNA (pgRNA) and subsequent viral DNA synthesis, thereby reducing the production of infectious virions. Mofesedine is currently being evaluated in clinical trials, often in combination with nucleos(t)ide analogs, to achieve deeper viral suppression and move toward a functional cure for HBV.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mofesedine.